Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M McLaughlin

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
JAMA Network Open|December 14, 2022
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of AgeFarid L Khan, Jennifer L Nguyen, Tanya G Singh, et al.
Scientific Reports|March 30, 2024
Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health systemDeborah E Malden, John M McLaughlin, Vennis Hong, et al.
Vaccine|February 23, 2025
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. statesKathleen M Andersen, Kristen E Allen, Rajeev M Nepal, et al.
Vaccines|March 26, 2022
COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021)Sarah M Hatcher, Stacy M Endres-Dighe, Frederick J Angulo, et al.
The Lancet. Infectious Diseases|March 18, 2023
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care systemJoseph A Lewnard, John M McLaughlin, Debbie Malden, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2022
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare systemJoseph A Lewnard, John M McLaughlin, Debbie Malden, et al.
Journal of the Pediatric Infectious Diseases Society|January 30, 2023
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative DesignSara Y Tartof, Timothy B Frankland, Laura Puzniak, et al.
American Journal of Therapeutics|May 1, 2024
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature ReviewAshley S Cha-Silva, Meghan B Gavaghan, Tobias Bergroth, et al.
Open Forum Infectious Diseases|February 12, 2024
Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022Yanhan Shen, McKaylee M Robertson, Sarah G Kulkarni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2018
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative DesignJohn M McLaughlin, Qin Jiang, Raul E Isturiz, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
JAMA Network Open|December 14, 2022
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of AgeFarid L Khan, Jennifer L Nguyen, Tanya G Singh, et al.
Scientific Reports|March 30, 2024
Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health systemDeborah E Malden, John M McLaughlin, Vennis Hong, et al.
Vaccine|February 23, 2025
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. statesKathleen M Andersen, Kristen E Allen, Rajeev M Nepal, et al.
Vaccines|March 26, 2022
COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021)Sarah M Hatcher, Stacy M Endres-Dighe, Frederick J Angulo, et al.
The Lancet. Infectious Diseases|March 18, 2023
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care systemJoseph A Lewnard, John M McLaughlin, Debbie Malden, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2022
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare systemJoseph A Lewnard, John M McLaughlin, Debbie Malden, et al.
Journal of the Pediatric Infectious Diseases Society|January 30, 2023
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative DesignSara Y Tartof, Timothy B Frankland, Laura Puzniak, et al.
American Journal of Therapeutics|May 1, 2024
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature ReviewAshley S Cha-Silva, Meghan B Gavaghan, Tobias Bergroth, et al.
Open Forum Infectious Diseases|February 12, 2024
Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022Yanhan Shen, McKaylee M Robertson, Sarah G Kulkarni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2018
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative DesignJohn M McLaughlin, Qin Jiang, Raul E Isturiz, et al.
Pageof 10